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ABSTRACT
Aims To determine whether the provision of contingency management using financial incentives to improve hepatitis B
vaccine completion in people who inject drugs entering community treatment represents a cost-effective use of health-
care resources. Design A probabilistic cost-effectiveness analysis was conducted, using a decision-tree to estimate the
short-term clinical and health-care cost impact of the vaccination strategies, followed by a Markov process to evaluate
the long-term clinical consequences and costs associated with hepatitis B infection. Settings and participants Data
on attendance to vaccination from a UK cluster randomized trial. Intervention Two contingency management options
were examined in the trial: fixed versus escalating schedule financial incentives. Measurement Life-time health-care
costs and quality-adjusted life years discounted at 3.5% annually; incremental cost-effectiveness ratios. Findings The
resulting estimate for the incremental life-time health-care cost of the contingency management strategy versus usual
care was £21.86 [95% confidence interval (CI) = –£12.20 to 39.86] per person offered the incentive. For 1000 people
offered the incentive, the incremental reduction in numbers of hepatitis B infections avoided over their lifetime was esti-
mated at 19 (95% CI = 8–30). The probabilistic incremental cost per quality adjusted life-year gained of the contingency
management programmewas estimated to be £6738 (95%CI= £6297–7172),with an 89%probability of being considered
cost-effective at a threshold of £20000 per quality-adjusted life years gained (97.60% at £30000). Conclusions Using
financial incentives to increase hepatitis B vaccination completion in people who inject drugs could be a cost-effective use
of health-care resources in the UK as long as the incidence remains above 1.2%.
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INTRODUCTION
Many countries include universal hepatitis B virus (HBV)
vaccination in their national immunization programmes
[1]. A few countries, including the United Kingdom, have
selective vaccination policies that target individuals at
increased risk of HBV infection or complications from the
disease, including people who inject drugs or who live with
injectors [2].
Despite these immunization programmes, HBV infections
remain an important public health problem among people
who inject drugs (PWID), even in many countries with
universal HBV vaccination [3]. In England and Wales, the
prevalence of current or past infection with HBV (measured
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by anti-HBc seropositivity) in current or past injectors has de-
clined over the last 20 years from 30% in 2003 to 17% in
2012, due in part to the introduction of a national prisonvac-
cination scheme in 2003 [4,5]. Monitoring data indicate that
among current and past injectors in contact with specialist
services, the self-reported hepatitis B vaccine uptake has
increased from50% in 2003 to 75% in 2012 [4]. Despite this
improvement in the self-reported vaccine uptake, completion
rates of HBV vaccination among current and past injectors,
even those using specialist services, remains low, and vaccine
uptake has plateaued in recent years [4]. Public health bene-
fits from HBV vaccination are not therefore realized fully in
PWID and transmission continues (albeit at lower levels),
with ongoing potential for community outbreaks [6,7].
Reasons for low completion of HBV vaccinations in commu-
nity settings include the poor adherence to treatment among
PWID and a high dropout from health-care services [8].
Contingency management has been proposed as an ap-
proach to improve patient adherence and completion of
public health interventions among hard-to-reach groups,
including HBV vaccination in PWID using community-
based services [9,10]. It uses incentives to encourage
attendance, reduce missed appointments and improve
successful intervention uptake [9]. Studies conducted in
Australia [11] and the United States [12,13] showed signif-
icantly improved adherence and completion of HBV vacci-
nation using contingency management in PWID. Similar
findings were observed in the United Kingdom in a recent
three-arm cluster randomized controlled trial where PWID
(including injectors, previous injectors and those at risk of
injecting in the future) undergoing treatment for heroin
dependence were randomized to either HBV vaccination
with or without contingency management [14].
There have been no economic evaluations of the use of
contingency management to enhance completion of HBV
vaccination among PWID in routine drug treatment
settings. This study evaluates whether the provision of
financial incentives to improve HBV vaccination completion
in PWID as undertaken in Weaver et al. [14] represents a
cost-effective use of health-care resources.
METHODS
Model
A decision-analytical model was constructed in Microsoft
Excel comprising a decision-tree to estimate the short-term
(i.e. around vaccination attempts) clinical and cost impact
of the vaccination strategies, followed by aMarkov chain to
evaluate the long-term clinical consequences and costs
associated with HBV infection of a hypothetical cohort of
PWID (including injectors, previous injectors and those at
risk of injecting in the future as defined in the trial) under-
going treatment over the lifetime in England and Wales.
The decision-analytical model compares two strategies:
HBV vaccination with and without contingency manage-
ment. Two contingency management options were exam-
ined in the trial (fixed versus escalating schedule financial
incentives). Data from the two options evaluated in the
trial were pooled in the economic model in the absence of
differences [14]. Further details on the trial and baseline
characteristics of patients included in the trial are available
in Weaver et al. [14].
The structure of the decision tree model is presented in
Fig. 1, with participants able to attend or not attend one,
two or all three ‘required’ vaccination appointments. At
the end of the HBV vaccination attempt, subjects within
the model can be vaccinated successfully (as a result of
one, two or three vaccine doses), or remain susceptible to
HBV (as a result of failing to begin vaccination, failing to
complete the vaccination course or as a result of a lack of
vaccine efficacy despite completing the course).
A Markov process (Fig. 2), using a 1-year cycle length,
was used to simulate the long-term clinical and cost
consequences of HBV-related infection. Themodel tracks pro-
gression through HBV disease states. Health states and tran-
sitions between health states were based on descriptions of
the natural history of HBV infection in existing systematic
reviews [15–18] and on published economic models, includ-
ing HBV [19–22]. The economic model differentiates periods
where individuals are at increased risk of HBV infection (are
in the PWID population) and where individuals at lower risk
of HBV infection (are ex-PWID).We assumed that individuals
at increased risk of HBV infection have an ongoing rate of
becoming immune to reflect theUK selective vaccination pol-
icy targeted to individuals at increased risk of HBV infection.
HBV incidence
The incidence of HBV infection among susceptible PWID in
the United Kingdom was estimated at 2.16% per year
using data from the national Unlinked Anonymous
Monitoring Survey among current and past injectors and
an approach similar to Sutton et al. [23]. Additional details
are provided in the Supporting information.
Direct data informing the incidence of HBV among
ex-PWID are lacking, which could range from zero to be
at the same level as in PWID. The base-case assumes
HBV infection incidence in ex-PWID equals the general
population incidence. General population HBV incidence
was estimated at 4.08 per 100000 using the annual inci-
dence of reported acute hepatitis B in England [24]
adjusted for under-reporting and asymptomatic cases [21].
Characteristics of the PWID population
The rate at which individuals cease injecting drugs [25]
was used as a proxy for the probability of leaving the PWID
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population and ceasing to be at high HBV infection risk
(Table 1). PWID can also become protected through
existing targeted vaccination programmes. We estimated
this rate of vaccination using the prevalence of self-
reported HBV vaccine uptake among current and past
injectors in 2011 (76% [4]) and converting this into the
Figure 1 Decision tree model for hepatitis B vaccination strategies. Back circle represent a decision node. CM = contingency management;
DNA = do not attend; TAU = treatment as usual; V1 = 1st vaccination appointment; V2 = 2nd vaccination appointment; V3 = 3rd vaccination
appointment
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annual probability of vaccination (28.8%), assuming a
constant uptake prevalence and PWID population size. To
account for partial protection in those reporting vaccination,
we assumed that 47.5% of self-reported vaccinations are
successful (based on the distribution of vaccine dose given
in prison [26] and evidence on the vaccine efficacy [27]).
The model accounts for elevated risk of all-cause
mortality [hazard ratio = 4.8; 95% confidence interval
(CI) = 4.6–5.0] for people in contact with drug-treatment
services compared with the general population. The
unadjusted mortality rate in the general population by
age was from UK life tables for England and Wales [28].
Natural history of HBV
The transition probabilities characterizing the natural history
of HBV were derived from the published literature (Table 1)
[15–18,29]. Lacking data for PWID, transitions between
HBV health states among the general population were used.
Effectiveness of the vaccination strategies
The economic analysis uses data from Weaver et al. [14].
The primary outcome in this trial was vaccination com-
pletion within 28 days. Attendance rates used in the
economic model are presented in Table 2. To reflect clinical
practice, we included delayed attendance (within a
3-month window from the start of the trial). The same
probability of attending a subsequent appointment was
used irrespective of whether the previous vaccination was
received on time.
Vaccine effectiveness
The effectiveness (seroprotection) associatedwith the receipt
of one, two and three doses was obtained from the literature
[27], as data were not collected routinely in the trial. In the
economic model, we assumed that participants receiving
one and three vaccine doses had a seroprotection of 15
and 76.4%, respectively [27], averaging these for
individuals receiving two doses. We assumed that
seroprotection was conferred after the last vaccine dose
(one, two or three doses), that immunity is life-long and that
the last dose was within 3 months from the first. Adverse
reactions to the vaccine are rare and were neglected [27].
Costs
A UK National Health Service perspective was employed,
and therefore only direct medical costs are considered.
Figure 2 Markov model of the long-term natural history of HBV infection. Transition between health states. People can die from general causes
(age-specific) in any of the health states (not shown here). Boxes in grey indicate excess mortality. CC = compensated cirrhosis; CHB = chronic
hepatitis; DC= decompensated cirrhosis; HBeAg = chronic hepatitis B e antigen; HBV = hepatitis B virus; HCC= hepatocellular carcinoma; LT = liver
transplantation; PWID = people who inject drugs
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Table 1 Model parameters used for annual transitions (unless stated) in the natural history Markov model.
Base-case
Lower range reported
in the literature
Upper range reported
in the literature Source
From ‘Susceptible PWID’
Probability of HBV infection 2.16% 1.76% 2.67% Estimated from a
catalytic model
Probability of future protection± 12.80% Derived from [4,25–27]
Probability of leaving PWID population 9.09% 5.00% 16.67% [25]
Remain susceptible—PWID 75.95%c
From ‘Susceptible—ex-PWID’
Probability of HBV infection 0.0041% 0%a 2.16%b Assumption
Remain in ‘Susceptible—ex-PWID’ 99.996c
Proportion of HBV infection that are
acute, fulminant and chronic
Proportion of HBV infection that are
acute (non-fulminant)d
93.20%c
Proportion of HBV infection that are
fulminantd
0.55% 0.30% 0.80% [21]
Proportion of HBV infection that are
chronicd
6.25% 2.50% 10.00% [29]
From ‘Fulminant HBV’
Proportion undergoing liver transplantd 13.50% 10.00% 17.00% [20]
Proportion of excess deathd 72.86% Derived from [21]
and [15]
Proportion of non-fatal fulminant HBV
not undergoing liver transplantd
13.64%d
From ‘Chronic HBV (HBeAg+ve)’
Probability of seroconversion (CHB-ve
or inactive)
11.50% 8.00% 15.00% [15–17]
Proportion seroconvert to CHB-ved 15.00% 10.00% 20.00% [15]
Probability of developing CC 4.00% 2.00% 6.00% [16–18]
Probability of developing HCC 0.35% 0.10% 0.60% [16,17]
Probability of excess death 0.55% 0.10% 1.00% [16]
Remain in chronic HBV (HBeAg+ve) 80.10%c
From ‘Chronic HBV (HBeAg-ve)’
Probability of developing CC 9.00% 8.00% 10.00% [18]
Probability of developing HCC 0.66% 0.01% 1.30% [17,18]
Probability of excess death 0.55% 0.10% 1.00% [16,17]
Remain in Chronic HBV (HBeAg-ve) 89.80%c
Chronic HBV (inactive) to:
Probability of developing CC 2.00% 1.00% 3.00% [17,18]
Probability of developing HCC 0.11% 0.02% 0.20% [17,18]
Probability clear HbsAg 1.25% 0.50% 2.00% [15]
Probability of excess death 0.03% 0.02% 0.04% [17]
Remain in chronic HBV (HBeAg inactive) 96.61%c
From ‘CC’
Probability of developing DC 3.50% 2.00% 5.00% [15–18]
Probability of developing HCC 2.85% 2.00% 3.70% [15–18]
Probability of excess death 3.20% 2.90% 3.50% [15–17]
Remain in CC 90.50%d
From ‘DC’
Probability of developing HCC 7.50% 7.00% 8.00% [18]
Probability of undergoing LT 4.40% 3.40% 5.40% [20]
Probability of excess death 35.00% 20.00% 50.00% [18]
Remain in DC 53.1%c
From ‘HCC’
Probability of undergoing LT 1.70% 1.50% 1.90% [20]
Probability of excess death 35.00% 20.00% 50.00% [18]
(Continues)
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Costs are discounted at 3.5% in the base-case as per the
National Institute for Health and Care Excellence recom-
mendation in the United Kingdom [30].
Staff, equipment and supervision costs were calculated
from the trial, based on data collected in 10 clinics for 116
patients enrolled into the trial irrespective of vaccination
arm. The costs estimated include adjustment for staff time
associated with non-attendance. Staff plus equipment costs
were estimated to be £15.68 ± 5.65 [standard deviation
(SD)] for individuals attending no vaccination appoint-
ment, £69.29 ± 12.66 for individuals attending only one
vaccination appointment, £98.91 ± 16.21 for individuals
attending only two vaccination appointments and
£112.35 ± 16.30 for individuals attending all three vacci-
nation appointments. The cost of training staff for
contingency management was excluded from the base-
case and the cost for Engerix (£12.99 per dose) [31] was
assumed, as benefits associated with prevention of hepatitis
A were not included. People receiving contingency man-
agement were assumed to receive a £10 voucher per vac-
cination appointment attendance. Finally, for participants
who attended at a later date an additional cost was
included for every unscheduled vaccination, equivalent to
the cost associated with non-attendance of the first vacci-
nation appointment (£16).
In the economic model, PWID have a probability of
vaccination through existing targeted programmes. A cost
per patient of £82 was applied to participants receiving
these vaccinations based on the proportion of patients
receiving one, two or three doses in prison [26], assuming
a cost of £29 for administration/preparation/administration
per dose [32] (based on 30-minute nurse time) and the cost
per vaccine dose (£12.99 per dose) [31].
Direct medical costs associated with the management
of HBV infection are taken from the literature and
assumptions when appropriate (Supporting information,
Table S1) [20,22,32–34].
Utilities
Health-related quality of life scores (utilities) are assigned to
each of the modelled health states based on trial estimates
or published literature. The baseline health utility for unin-
fected PWID and ex-PWID was estimated as 0.57 ± 0.34
(range = –0.43 to 1.00) based on the mean (SD) Euroqol
5 dimensions score in trial subjects. The decrements in
quality of life for patients with active chronic HBV, inactive
chronic HBV, compensated cirrhosis, decompensated
cirrhosis, hepatocellular carcinoma and post-liver transplant
was taken from Ong et al. [35] in non-PWID. Individuals
with fulminant hepatitis were assumed to have the same
decrement in qualityof life as individualswith hepatocellular
carcinoma. Similarly, the decrement in quality of life in the
first year following transplantation was taken as mean of
Table 1. (Continued)
Base-case
Lower range reported
in the literature
Upper range reported
in the literature Source
Remain in HCC 63.30%c
From ‘LT’
Probability of excess death—first year 21.00% 15.00% 27.00% [22]
Probability of excess death—
subsequent years
5.00% 3.00% 7.00% [22]
aassumption; bAssumed to be the same as people who inject drugs (PWID); cremaining probabilities (one minus probabilities above), ± calculated from
self-reported vaccination, leaving rate, number of vaccine dose received in prison and vaccine effectiveness; dproportion. HBV = hepatitis B virus;
CHB = chronic hepatitis; LT = liver transplantation; CC = compensated cirrhosis; HCC = hepatocellular carcinoma; DC = decompensated cirrhosis;
HBeAg = chronic hepatitis B e antigen.
Table 2 Attendance at hepatitis B virus (HBV) vaccination
appointments.
Treatment
as usual CM
1st vaccination appointment
Expected to attend 67 143
Did not attend 33 49% 34 24%
Attended on time 21 31% 97 68%
Delayed attendance 13 19% 12 8.%
2nd vaccination appointment
Expected to attend 31 105
Did not attend 8 26% 13 12%
Attended on time 15 48% 84 80%
Delayed attendance 8 26% 8 8%
3rd vaccination appointment
Expected to attend 22 85
Did not attend 8 36.% 15 18%
Attended on time 7 32% 64 75%
Delayed attendance 7 32% 6 7%
CM = contingency management. It should be noted that the number of
individual expected to attend is different to the number of individuals who
attended the previous round, as some individuals were already immune
and therefore did not need to return for another vaccine dose.
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the decrement in quality of life for patients with hepatocellu-
lar carcinoma and post-transplant patients (Supporting
information, Table S2). We assumed that individuals with
acute symptomatic hepatitis had a reduction in quality-
adjusted life years of 0.0255 (accounting for the duration
of illness) [36] and no reduction in quality of life for
individuals with asymptomatic hepatitis. Finally, no decre-
ment in quality of life associated with vaccination was
considered [27].
Analysis
Results are presented probabilistically to take account of
the simultaneous effect of uncertainty relating to model
parameter values. A total number of 1000 simulations
were performed in order to provide sufficient information
on uncertainty. The results of the probabilistic analysis
are also presented as cost-effectiveness planes and accept-
ability curves.
A number of one-way sensitivity analyses were con-
ducted. Results are presented in the form of a Tornado
diagram.
RESULTS
For 1000 people offered the incentive, we estimated the
number of HBV infections to be 44, compared with 62 in
the absence of financial incentives (reduction in numbers
of HBV infections of 19; 95% CI = 8–30), based on our
mathematical model under our base-case assumptions.
The cost of delivering HBV vaccination (including staff
costs, equipment, vaccine cost and cost associated with
contingency management) was estimated to be £156.73
(95% CI = £126.44–181.17) per participant receiving
the intervention and £78.36 (95% CI = £52.50–101.62)
per participant under treatment as usual. The model
predicted that 48. 77% (95% CI = 43.08–52.86%) of
participants receiving contingency management would
be protected against HBV infection, compared with
26.54% (95% CI = 19.36–32.65%) for treatment as usual.
Providing contingency management in the manner of
the trial would lead to a small gain in life-years (0.0045;
95% CI = 0.0017–0.0075) and quality-adjusted life-years
(0.0032; 95% CI = 0.0013–0.0054) per patient, but at an
increased cost (£21.86; 95% CI = –£12.20 to 39.86),
despite the reduction in expected HBV management costs
(£53.34; 95% CI = –£96.24 to –33.88) over a life-time.
Under our base-case assumptions, the probabilistic
incremental cost-effectiveness ratio associated with the
provision of modest financial incentives to increase vacci-
nation completion in PWID in contact with specialist
services was estimated to be £6738 (95% CI = £6297–
7172) per quality-adjusted life-years gained using a life-
time horizon.
The economic analysis was most sensitive to the time
horizon, the chronicity rate following HBV exposure, the
duration individuals remain at increased risk of HBV infec-
tion (i.e. remain PWID), the incidence rate for HBV,
discount rates for both costs and benefits and the cost
associated with training/supervision (Fig. 3).
A major uncertainty in the model relates to the inci-
dence of HBV infection in England andWales among PWID
and ex-PWID. In the base-case we assumed the incidence
in PWID to be approximately 2.16% (95% CI = 1.76–
2.67%) based on results estimated from the Unlinked
Anonymous Monitoring Survey. However, there is uncer-
tainty around this value. Figure 4 shows that under our
current base-case assumptions (assuming the incidence
of HBV in ex-PWID to be the same as the general popula-
tion), the incidence of HBV in PWID needs to be greater
than 1.2% per year for the incremental cost per quality-
adjusted life years gained to fall below a cost-effectiveness
threshold of £20000 per quality-adjusted life years gained.
The incremental cost per quality-adjusted life years gained
also improves as the incidence of HBV in ex-PWID becomes
closer to the incidence in PWID and may lead to cost-
savings (data not shown).
The cost-effectiveness acceptability curve and cost-
effectiveness planes are presented in Fig. 5a,b). The use of
contingency management have 88.51 and 97.60% proba-
bilities of being considered cost-effective at a willingness to
pay of £20000 and 30000 per quality-adjusted life years
gained, respectively, under our base-case assumptions.
DISCUSSION
Contingency management using financial incentives to
improve completion of hepatitis B vaccination in people
injecting drugs entering community-based services is likely
to be cost-effective under current willingness to pay [30].
This is the first study to undertake an economic evaluation
to calculate the cost-effectiveness of providing contingency
management—financial incentives—to PWID to enhance
hepatitis B vaccination completion.
Key strengths of this study include that it is based on a
well-conducted cluster randomized controlled trial of
contingency management versus treatment as usual in
12 specialist National Health Service (NHS) services pro-
viding opiate substitution treatment in England [14]. The
trial included direct measurement of the costs of delivering
contingency management including staff time, equipment
and consumables.
The best available evidence was used. The structure of
the model follows the representation of the natural course
of HBV in previous systematic reviews describing the
natural history of HBV infection [15–18] and previous
economic evaluations [19–22]. The incidence of HBV
was estimated from cross-sectional survey data from the
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national Unlinked Anonymous Monitoring Survey, which
provide robust estimates of prevalence trends of HBV infec-
tion and self-reported vaccination among current and past
injectors in the United Kingdom.
The generalizability of our results requires careful
consideration. The United Kingdom does not have a pro-
gramme of universal HBV vaccination. However, intensive
targeted efforts in the United Kingdom have resulted in
Figure 4 Effect of varying the base-case incidence of HBV infection in PWID on the incremental cost per QALY gained of CM versus TAU. The blue
solid line represents the incremental cost-effectiveness ratio (ICER) for CM compared with TAU assuming different incidence of Hepatitis B. The black
dashed line represents the £20 000 per QALY gained WTP threshold. CM = contingency management; HBV = hepatitis B virus; QALY = quality
adjusted life years; TAU = treatment as usual; WTP = willingness to pay
Figure 3 Univariate sensitivity analysis (most sensitive parameters). White line represents the base-case probabilistic incremental cost-effectiveness
ratio (ICER). CC = compensated cirrhosis; CM = contingency management; HBV = hepatitis B virus; PWID = people who inject drugs
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improved coverage of HBV vaccination among PWID, and
while the cohorts vaccinated at birth in countries that did
implement universal programmes may now be approaching
the age of first injection, coverage may be lowest among
those most likely to inject. Similar trials conducted in
Australia [11] and the United States [12,13] showed that it
is possible to improve adherence to and completion of HBV
vaccination programmes significantly using contingency
management.
Another key factor in generalizability is the existing rate
of HBV incidence. Studies conducted in other countries
such as Australia, the United States and the Netherlands
report a HBV incidence in current and past injectors
ranging between 1.8 and 30.7 per 100 person-years
[37], but these studies are dated. There is also likely to be
large subnational variation. However, our sensitivity anal-
ysis suggests that the incremental cost-effectiveness ratio
(ICER) would fall below £20000 per QALY gained when
the incidence of HBV in PWID ismore than 1.20% per year.
As with any economic evaluation, there are some
limitations. There are uncertainties on the future probabil-
ity for a susceptible PWID to be reached by current
targeted vaccination programme in England and Wales,
the duration individuals remain at increased risk of HBV
infection and the risk of HBV infection among ex-PWID.
It is also difficult to predict seroprotection in this patient
group, as some PWIDs are protected after one vaccination
and some are not even after three doses. There is also
Figure 5 (a) Cost-effectiveness acceptability curves for the probability that CM is more cost effective than usual care. The blue solid line represents
the probability for CM to be cost-effective at different WTP threshold. The red solid line represents the probability for TAU to be cost-effective at
differentWTP threshold. (b) The black dashed line represents the £20 000 per QALY gainedWTP threshold. Cost effectiveness plane for CM versus
TAU. Solid points represent incremental cost and QALY results (intervention arm minus control arm) from the probabilistic analysis for each of the
1000 samples. The black dashed line represents the £20 000 per QALY gained WTP threshold. CM = contingency management; QALY = quality
adjusted life years; TAU = treatment as usual; WTP = willingness to pay
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uncertainty concerning the efficacy of incomplete vaccine
course and the time to protection. Decrements in utilities
associated with hepatitis B were taken from non-UK data
among non-PWID data. PWID may experience different
decrements in quality of life due to high propensity for
comorbidities. Transitions between HBV health states
among PWID were also taken from studies conducted in
cohorts that did not entirely comprise PWID. In order not
to overestimate the benefits of vaccination, we allowed for
life-course reductions in risk of HBV infection by introduc-
ing an ex-PWID state. In the absence of specific data for this
group, we conservatively assumed the risk of HBV infection
among ex-PWID to be the same as the general population.
In reality, ex-PWIDmay have higher exposure to HBV than
the general population, e.g. due to recommencing injecting
or sexual transmission.
In the trial, contingency management was shown to
increase vaccination completion rapidity, therefore reduc-
ing the period at risk of infection. This is not captured in
the economic model. Similarly, attendance at scheduled
appointments was increased in patients receiving the inter-
vention, which may therefore reduce the work-load in
clinic and increase efficiency and therefore may lead to a
reduction in costs.
Further development of the modelling approach could
consider secondary transmission (dynamic/transmission
modelling) of HBV and the indirect effect of vaccination
(herd immunity). The modelling presented here also does
not consider outbreaks or co-infection associated with
hepatitis A, hepatitis C and human immunodeficiency virus.
Our work suggests that further research is needed to
determine whether ex-PWID carry the same risk as PWID.
Further research is also required to understand the
dynamics of PWID and secondary transmission as well as
the natural history in PWID and impact of hepatitis B on
quality of life.
The central implication of our study for practice is that
contingency management should be considered seriously
as a worthwhile additional investment to improve health
outcomes. The United Kingdom has seen a sustained pro-
gramme to improve HBV vaccination coverage in high-risk
groups, including offering HBV vaccination in syringe
exchanges and prisons. Contingency management is not
a replacement for these efforts, but was able to additional
benefits in a cost-effective manner. Provision of lower
financial incentives may potentially be as effective, and
determining the optimal incentive would be advantageous.
In the trial, attendance at the first vaccination appointment
was not different between the two strategies (75.4 versus
76.9%), despite different financial incentives (£5 versus
10) [14].
Wider use of contingency management will require
guidance and monitoring. In clinical practice, people may
not be screened so thoroughly for eligibility, resulting in
more doses given to people with previous immunity. PWID
may also not disclose their vaccination status to be eligible
to receive the financial incentives. This has some cost impli-
cations, as more doses may be given, but it is unclear
whether the additional cost is outweighed by the benefits.
In practice, it is advised to take blood when possible and
give a vaccine dose if uncertain of someone’s protective
immunity.
This economic evaluation examined only the provision
of HBV vaccination. Some sites in the trial offered a biva-
lent vaccine providing protection for both HBVand hepati-
tis A, at little extra cost. The demonstrated malleability of
health-adherence behaviours in this population could
potentially be leveraged to boost other interventions for
little extra cost, e.g. hepatitis C virus testing. If provided
in parallel to HBV vaccination, or even as stand-alone
interventions with contingency management, might lead
to more PWID tested for hepatitis C virus coming back to
get their results, and more of those testing positive then
entering a hepatitis C virus care pathway. Evaluation of
such combined strategies will require additional research.
Finally, it is unclear whether results are transferable to
other injectors, notably people who inject image and
performance drugs. [38].
CONCLUSIONS
This is the first economic evaluation examining the cost-
effectiveness of providing contingency management using
financial incentives to PWID in contact with specialist
services in order to enhance hepatitis B vaccination com-
pletion. We find that using contingency management to
increase vaccination completion among this group is
cost-effective under current willingness to pay thresholds.
However, there are considerable uncertainties that need
fuller attention in future studies, notably the paucity of
evidence on the incidence of HBV infection incidence and
the likelihood of PWID being reached by existing targeted
vaccination programmes such as prison vaccination in
the future. The intervention is likely to be more cost-
effective in settings with higher risk of HBV infection or if
the occurrence of outbreaks is considered.
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